Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
EDAP TMS S.A. is a France-based medical technology company specializing in therapeutic ultrasound solutions for urology. The company operates within the medical devices and healthcare technology industries, with a primary focus on non-invasive and minimally invasive treatments for prostate diseases and urinary stones. EDAP’s core offerings are built around proprietary high-intensity focused ultrasound (HIFU) technology and advanced extracorporeal shock wave lithotripsy systems.
The company’s principal revenue drivers are its prostate cancer treatment platform Focal One®, its robotic HIFU solutions, and its lithotripsy and endourology product lines. EDAP primarily serves hospitals, academic medical centers, and specialty urology clinics, positioning itself as a technology leader in focal therapy for prostate cancer. Founded in 1979, EDAP evolved from a research-driven ultrasound technology company into a publicly listed global medical device manufacturer, with its American Depositary Shares traded on Nasdaq under the ticker EDAP.
Business Operations
EDAP operates through two primary business segments: High Intensity Focused Ultrasound (HIFU) and Distribution and Services. The HIFU segment includes the development, manufacturing, and commercialization of therapeutic ultrasound devices, notably the Focal One® system used for the treatment of localized prostate cancer. Revenue in this segment is generated through system sales, recurring disposables, maintenance contracts, and service agreements.
The Distribution and Services segment encompasses the sale and servicing of lithotripsy, endourology, and diagnostic imaging equipment, including shock wave lithotripters used to treat kidney and ureteral stones. EDAP conducts operations across Europe, North America, and Asia, supported by direct sales teams and third-party distributors. The company controls its core HIFU technology internally and operates through subsidiaries including EDAP TMS France, EDAP TMS Inc., and EDAP TMS Asia.
Strategic Position & Investments
EDAP’s strategic direction centers on expanding adoption of focal therapy as a standard treatment option for localized prostate cancer. The company has invested heavily in clinical studies, regulatory approvals, and physician training programs to support broader reimbursement and guideline inclusion of HIFU-based therapies. A key strategic milestone has been U.S. FDA clearance and growing commercial penetration of Focal One® in the American market.
In addition to organic growth, EDAP has pursued selective acquisitions to strengthen its urology portfolio, including the acquisition of Exact Imaging (completed in 2022), which added high-resolution micro-ultrasound imaging technology for prostate cancer detection. The integration of imaging and therapeutic platforms is a core component of EDAP’s long-term strategy, positioning the company at the intersection of precision diagnostics and minimally invasive treatment.
Geographic Footprint
EDAP is headquartered in Lyon, France, and maintains a significant operational presence in North America, particularly the United States, which represents a major growth market. The company also operates across Western Europe, with established commercial infrastructure in countries such as Germany, Italy, and the United Kingdom.
Beyond Europe and North America, EDAP has a presence in Asia-Pacific, including operations and distribution partnerships in China, Japan, and South Korea. Its global footprint supports both direct sales and distributor-led models, enabling international adoption of its urology platforms and reinforcing its influence in key healthcare markets across multiple continents.
Leadership & Governance
EDAP is led by an executive team with extensive experience in medical technology, urology, and global healthcare commercialization. The company emphasizes a leadership philosophy focused on clinical validation, long-term innovation, and disciplined execution aligned with regulatory and reimbursement pathways.
Key members of EDAP’s leadership include:
- Marc Oczachowski – Chief Executive Officer
- Cédric O’Neill – Chief Financial Officer
- Thierry de Geyter – Chief Operating Officer
- Gary Onik, M.D. – Chief Medical Officer
- Eric Dumas – Vice President, Research & Development
The board of directors provides governance oversight consistent with European corporate standards and U.S. public market requirements, reflecting EDAP’s dual presence as a French issuer with Nasdaq-listed securities.